RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow

Journal of Molecular Medicine

Volumn 92, Issue 1, 2014, Pages 77-92

  Xu, Jingjing ^a   Zhou, Peng ^a   Wang, Wenjuan ^a   Sun, Aining ^a,b   Guo, Feng ^a  

^a SOOCHOW UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Cell survival; CLL; Proteasome inhibitor; RelA; RelB

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; FLUDARABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB;

ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BONE MARROW; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL FUNCTION; CELL NUCLEUS; CELL SURVIVAL; CHEMOSENSITIVITY; CHRONIC LYMPHATIC LEUKEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; LEUKEMIA CELL LINE; LEUKOCYTE ADHERENCE; LEUKOCYTE MIGRATION; MALE; MIDDLE AGED; MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA CELL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW CELLS; CELL SURVIVAL; CHEMOKINES; CHROMOSOME ABERRATIONS; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NF-KAPPA B; PROTEASOME INHIBITORS; RECEPTOR, NOTCH1; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB;

EID: 84891889814     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-013-1081-6     Document Type: Article

References (54)

1. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S (2010) From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10:37-50. doi: 10.1038/nrc2764
2. Gaidano G, Foa R, Dalla-Favera R (2012) Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest 122:3432-3438. doi: 10.1172/JCI64101
3. Puente XS, Pinyol M, Quesada V, Conde L, Ordonez GR, Villamor N, Escaramis G, Jares P, Bea S, Gonzalez-Diaz M et al (2011) Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475:101-105. doi: 10.1038/nature10113
4. Rossi D, Fangazio M, Rasi S, Vaisitti T, Monti S, Cresta S, Chiaretti S, Del Giudice I, Fabbri G, Bruscaggin A et al (2012) Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 119:2854-2862. doi: 10.1182/blood-2011-12-395673
5. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ (2000) Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 164:2200-2206 (Pubitemid 30108780)
6. Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sanchez A, Martin-Saavedra FM, Ballester S, Garcia-Marco J, Jorda J, Durantez A (2004) A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 18:1391-1400. doi: 10.1038/sj.leu.24033982403398 (Pubitemid 39136749)
7. Lopez-Guerra M, Colomer D (2010) NF-kappaB as a therapeutic target in chronic lymphocytic leukemia. Expert Opin Ther Targets 14:275-288. doi: 10.1517/14728221003598930
8. Vallabhapurapu S, Karin M (2009) Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 27:693-733. doi: 10.1146/annurev.immunol.021908.132641
9. DiDonato JA, Mercurio F, Karin M (2012) NF-kappaB and the link between inflammation and cancer. Immunol Rev 246:379-400. doi: 10.1111/j.1600-065X.2012. 01099.x
10. Guo F, Tanzer S, Busslinger M, Weih F (2008) Lack of nuclear factor-kappa B2/p100 causes a RelB-dependent block in early B lymphopoiesis. Blood 112:551-559. doi: 10.1182/blood-2007-11-125930
11. Weih F, Caamano J (2003) Regulation of secondary lymphoid organ development by the nuclear factor-kappaB signal transduction pathway. Immunol Rev 195:91-105 (Pubitemid 37153456)
12. Pickering BM, de Mel S, Lee M, Howell M, Habens F, Dallman CL, Neville LA, Potter KN, Mann J, Mann DA et al (2007) Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene 26:1166-1177. doi: 10.1038/sj.onc.1209897
13. Romano MF, Lamberti A, Tassone P, Alfinito F, Costantini S, Chiurazzi F, Defrance T, Bonelli P, Tuccillo F, Turco MC et al (1998) Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 92:990-995 (Pubitemid 28355483)
14. Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, Jordan CT, Neelakantan S, Crooks PA, Burnett AK et al (2008) The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 111:4681-4689. doi: 10.1182/blood-2007-11-125278
15. Hewamana S, Lin TT, Rowntree C, Karunanithi K, Pratt G, Hills R, Fegan C, Brennan P, Pepper C (2009) Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. J Clin Oncol 27:763-769. doi: 10.1200/JCO.2008.19.1114
16. Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM (2010) Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 115:3541-3552. doi: 10.1182/blood-2009-09-243535
17. dos Santos NR, Williame M, Gachet S, Cormier F, Janin A, Weih D, Weih F, Ghysdael J (2008) RelB-dependent stromal cells promote T-cell leukemogenesis. PLoS One 3:e2555. doi: 10.1371/journal.pone.0002555
18. Guo F, Sun A, Wang W, He J, Hou J, Zhou P, Chen Z (2009) TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells. Mol Immunol 46:2441-2448. doi: 10.1016/j.molimm.2009.05.178
19. Ranuncolo SM, Pittaluga S, Evbuomwan MO, Jaffe ES, Lewis BA (2012) Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival. Blood 120:3756-3763. doi: 10.1182/blood-2012-01-405951
20. Guo F, Kang S, Zhou P, Guo L, Ma L, Hou J (2011) Maspin expression is regulated by the non-canonical NF-kappaB subunit in androgen-insensitive prostate cancer cell lines. Mol Immunol 49:8-17. doi: 10.1016/j.molimm.2011.07. 013
21. Yilmaz ZB, Weih DS, Sivakumar V, Weih F (2003) RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF. EMBO J 22:121-130. doi: 10.1093/emboj/cdg004 (Pubitemid 36091275)
22. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, Murphy EJ, Koduru P, Ferrarini M, Zupo S et al (2005) In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 115:755-764. doi: 10.1172/JCI23409 (Pubitemid 40322252)
23. Aalto Y, El-Rifa W, Vilpo L, Ollila J, Nagy B, Vihinen M, Vilpo J, Knuutila S (2001) Distinct gene expression profiling in chronic lymphocytic leukemia with 11q23 deletion. Leukemia 15:1721-1728 (Pubitemid 33061839)
24. Burger JA (2011) Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2011:96-103. doi: 10.1182/asheducation-2011.1.96
25. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B, Gibellini F, Njuguna N, Lee E, Stennett L et al (2011) The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117:563-574. doi: 10.1182/blood-2010-05-284984
26. Shukla A, Chaturvedi NK, Ahrens AK, Cutucache CE, Mittal AK, Bierman P, Weisenburger DD, Lu R, Joshi SS (2013) Stromal tumor microenvironment in chronic lymphocytic leukemia: regulation of leukemic progression. J Leuk 1:113-121. doi: 10.4172/2329-6917.1000113
27. Furman RR (2010) Prognostic markers and stratification of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010:77-81. doi: 10.1182/asheducation-2010.1.77
28. Coscia M, Pantaleoni F, Riganti C, Vitale C, Rigoni M, Peola S, Castella B, Foglietta M, Griggio V, Drandi D et al (2011) IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia 25:828-837. doi: 10.1038/leu.2011.12
29. Xu Y, Josson S, Fang F, Oberley TD, St Clair DK, Wan XS, Sun Y, Bakthavatchalu V, Muthuswamy A, St Clair WH (2009) RelB enhances prostate cancer growth: implications for the role of the nuclear factor-kappaB alternative pathway in tumorigenicity. Cancer Res 69:3267-3271. doi: 10.1158/0008-5472.CAN- 08-4635
30. Holley AK, Xu Y, St Clair DK, St Clair WH (2010) RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Ann N Y Acad Sci 1201:129-136. doi: 10.1111/j.1749-6632.2010. 05613.x
31. Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, Galtier F, Chalbos D, Sonenshein GE (2007) Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol 9:470-478. doi: 10.1038/ncb1559 (Pubitemid 46511081)
32. Wang X, Belguise K, O'Neill CF, Sanchez-Morgan N, Romagnoli M, Eddy SF, Mineva ND, Yu Z, Min C, Trinkaus-Randall V et al (2009) RelB NF-kappaB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1. Mol Cell Biol 29:3832-3844. doi: 10.1128/MCB.00032-09
33. Mineva ND, Wang X, Yang S, Ying H, Xiao ZX, Holick MF, Sonenshein GE (2009) Inhibition of RelB by 1,25-dihydroxyvitamin D3 promotes sensitivity of breast cancer cells to radiation. J Cell Physiol 220:593-599. doi: 10.1002/jcp.21765
34. Endo T, Nishio M, Enzler T, Cottam HB, Fukuda T, James DF, Karin M, Kipps TJ (2007) BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood 109:703-710. doi: 10.1182/blood-2006-06-027755 (Pubitemid 46105972)
35. Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, Marasca R, Laurenti L, Bruscaggin A, Cerri M et al (2012) Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 119:521-529. doi: 10.1182/blood-2011-09-379966
36. Villamor N, Conde L, Martinez-Trillos A, Cazorla M, Navarro A, Bea S, Lopez C, Colomer D, Pinyol M, Aymerich M et al (2012) NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia. doi: 10.1038/leu.2012.357
37. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV (1996) Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 92:97-103 (Pubitemid 26018774)
38. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P (1998) Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 91:2387-2396
39. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ et al (2009) Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 114:4441-4450. doi: 10.1182/blood-2009-07-233718
40. Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC, Dalton WS, Tao J (2007) Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia 21:1521-1531. doi: 10.1038/sj.leu.2404723 (Pubitemid 46965295)
41. Ding W, Nowakowski GS, Knox TR, Boysen JC, Maas ML, Schwager SM, Wu W, Wellik LE, Dietz AB, Ghosh AK et al (2009) Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br J Haematol 147:471-483. doi: 10.1111/j.1365-2141.2009.07868.x
42. Cols M, Barra CM, He B, Puga I, Xu W, Chiu A, Tam W, Knowles DM, Dillon SR, Leonard JP et al (2012) Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. J Immunol 188:6071-6083. doi: 10.4049/jimmunol.1102066
43. Perez-Galan P, Roue G, Lopez-Guerra M, Nguyen M, Villamor N, Montserrat E, Shore GC, Campo E, Colomer D (2008) BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia 22:1712-1720. doi: 10.1038/leu.2008.175
44. Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O'Brien S, Sheng S, Esseltine DL, Keating MJ (2006) Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer 107:916-924. doi: 10.1002/cncr.22097 (Pubitemid 44291139)
45. Hauer J, Puschner S, Ramakrishnan P, Simon U, Bongers M, Federle C, Engelmann H (2005) TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci U S A 102:2874-2879. doi: 10.1073/pnas.0500187102 (Pubitemid 40299884)
46. Bergsagel PL (2009) TRAF3 in B cells: too much, too little, too bad. Blood 113:4481-4482. doi: 10.1182/blood-2009-01-199810
47. Garber K (2007) Gene mutation revelation points to new target for myeloma treatment, studies say. J Natl Cancer Inst 99:1362-1364. doi: 10.1093/jnci/djm164
48. Balakrishnan K, Burger JA, Wierda WG, Gandhi V (2009) AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 113:149-153. doi: 10.1182/blood-2008-02-138560
49. Masood A, Chitta K, Paulus A, Khan AN, Sher T, Ersing N, Miller KC, Manfredi D, Ailawadhi S, Borrelo I et al (2012) Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. Br J Haematol 157:59-66. doi: 10.1111/j.1365-2141.2011. 08984.x
50. Schrottner P, Leick M, Burger M (2010) The role of chemokines in B cell chronic lymphocytic leukaemia: pathophysiological aspects and clinical impact. Ann Hematol 89:437-446. doi: 10.1007/s00277-009-0876-6
51. Burger JA, Burger M, Kipps TJ (1999) Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94:3658-3667
52. Kay NE, Shanafelt TD, Strege AK, Lee YK, Bone ND, Raza A (2007) Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch". Leuk Res 31:899-906. doi: 10.1016/j.leukres.2006. 11.024 (Pubitemid 46856727)
53. Guo F, Weih D, Meier E, Weih F (2007) Constitutive alternative NF-kappaB signaling promotes marginal zone B-cell development but disrupts the marginal sinus and induces HEV-like structures in the spleen. Blood 110:2381-2389. doi: 10.1182/blood-2007-02-075143 (Pubitemid 47523158)
54. Chiorazzi N, Ferrarini M (2011) Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 117:1781-1791. doi: 10.1182/blood-2010-07-155663